Insulin

Cipla gets approval to market Afrezza insulin inhalation powder in India

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India. Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus. By bringing a game-changing, patient-centred solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease, the Mumbai-based company said in a statement. Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins which are given as injections. Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream. Afrezza starts working as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals. T

Torrent Pharma Q2FY25 results: Net profit rises 17%, misses estimates

At an operational level, Torrent Pharma's earnings before interest, tax, depreciation, and amortisation stood at Rs 939 crore, with an Ebitda margin of 32.5 per cent

All you need to know about Type 1.5 diabetes, a mix of type 1 and type 2

Also known as latent autoimmune diabetes in adults (LADA), type 1.5 diabetes has features of both type 1 and type 2 diabetes

On hottest days, hospitalisation risk doubled in people having sugar: Study

On the hottest days, risk of hospitalisation for people with metabolic disorders such as those of sugar and blood pressure, and obesity, almost doubled as compared to days recording comfortable temperatures, a new study has found. The research analysing hospital admissions related to high temperatures during summer over more than a decade in Spain found that extreme heat impacted people with these conditions the most. "There are a number of reasons to explain this. For example, in people with obesity, heat loss responses work less efficiently, as body fat acts as an insulator, making them more susceptible to heat disorders," said Hicham Achebak, a researcher at the Barcelona Institute for Global Health. Higher levels of air pollution further appeared to worsen the risk of hospital admission for people with these conditions, including diabetes, the researchers said. The study also found that on hotter days, men showed a higher risk of hospital admission due to injuries, while women

Delhi CM Kejriwal given insulin after spike in sugar level: Tihar officials

Delhi Chief Minister Arvind Kejriwal has been administered a "low dose" of insulin after his blood sugar level spiked, officials of Tihar jail here said on Tuesday. "Kejriwal was given two units of low dose insulin on Monday evening on the advice of AIIMS doctors", a Tihar official said. His blood sugar level reading was found to be 217 around 7 pm, following which the doctors at Tihar looking after him decided to give him the insulin, the official said. AIIMS specialists, during a video conference with the chief minister on April 20, had advised Tihar doctors that insulin could be given to him if his sugar level crosses a certain level, he added. Meanwhile, AAP sources said Kejriwal's blood sugar level had crossed 320 in Tihar. They said this is the first time that insulin has been given to him in the jail even as his sugar level had been increasing for some time. The Delhi chief minister was arrested on March 21 by the Enforcement Directorate (ED) in connection with a ...

Asking for insulin daily: Kejriwal writes to Tihar superintendent

Delhi Chief Minister Arvind Kejriwal on Monday wrote to superintendent of Tihar jail where he is lodged since April 1, claiming he has been asking for insulin every day and that AIIMS doctors never said there was no reason to worry about his diabetic condition. His letter to the superintendent comes a day after the Tihar administration issued a statement stating they had arranged his video conference with senior specialists from AIIMS during which neither "the issue of insulin was raised by Kejriwal, nor was it suggested by the doctors". The chief minister alleged that the Tihar administration issued a "false and misleading" statement under "political pressure". There was no immediate reaction from Tihar jail authorities on Delhi chief minister's allegations. Delhi cabinet minister Atishi shared Kejriwal's letter on her X handle. The chief minister rejected the jail administration's claim that the issue of insulin was never raised by him in his consultations with the doctors. "Th

Eris buys India formulation biz of Biocon Biologics for Rs 1,242 crore

The deal would enable Eris' entry into the Rs 3k cr injectables market, and it would become one of major players in the insulins segment with the acquisition of Biocon Biologic's Basalog and Insugen

Biocon to sell branded formulations biz to Eris Lifesciences for $150 mn

Biocon had earlier sold its dermatology and nephrology branded formulation businesses to Eris for Rs 350 crore in November last year

Incisionless device could revolutionise treatment for metabolic diseases

A completely incisionless device that replicates metabolic surgery without making any cuts could surpass current technologies for managing conditions such as severe obesity and type 2 diabetes, a team led by an Indian researcher has found. The ForePass device could provide unmatched treatment for millions of people who reject invasive surgery or do not respond to drugs, the researchers said. The study led by Manoel Galvao Neto, from Sri Aurobindo Medical College in Madhya Pradesh, found that the ForePass endoscopic showed extraordinary efficacy in treating conditions such as severe obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Results, published in the journal Gut, revealed a 79 per cent reduction in weight gain compared to the control group, suggesting it may be substantially more effective than common metabolic surgeries like gastric bypass. The study also showed substantial improvements in how the body handles insulin and reduces glucose

USFDA rejects proposed Biocon's Insulin Aspart application in CRL

Biotechnology major Biocon on Saturday said the US health regulator has issued a complete response letter for Biocon Biologics' application for Insulin Aspart, a proposed biosimilar for diabetes treatment. The US Food and Drug Administration (USFDA) has issued a Complete Response Letter (CRL) to convey to the company that its initial review of an application is complete, and it cannot approve the application in its present form. "The CRL did not identify any outstanding scientific issues with the product. The CRL references the requirement for a satisfactory resolution of deficiencies from the pre-approval inspection (PAI) of our Malaysia facility for Insulin Aspart, held in August 2022," Biocon spokesperson said in a regulatory filing. The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022 that the agency found to be adequate and indicated that it would require a re-inspection of the Malaysia facility prior to the approval of the ..

Insulin maker GeneSys to invest $50-60 mn to set up plant in Hyderabad

Biotechnology company GeneSys Biologics Pvt Ltd is planning to invest USD 50-60 million to set up a new large-scale recombinant bulk manufacturing facility in Genome Valley here for the production of insulin analogues. The insulin analogues (medical insulin that are altered forms of the human hormone insulin) will be produced in the recombinant bulk manufacturing facility in which purified bulk insulin will be derived through fermentation. An official press release said the Hyderabad-based company has already invested approximately USD 50 million in its Genome Valley plant. Telangana IT and Industries Minister K T Rama Rao expressed delight over the expansion plans of GeneSys saying it will not only contribute to the growth of Hyderabad's biotech sector but also facilitate the company's ongoing collaboration with US-based Civica Rx. GeneSys has partnered with Civica Rx, a US non-profit generic drug company, to manufacture and distribute affordable insulin. The minister congratulat

Trying to lock in vendors who don't want to buy from China: Biocon CEO & MD

Siddharth Mittal, CEO & MD, Biocon, elaborates on his plans to grow this business further

A panoramic history of the cell

Pulitzer Prize winner Siddhartha Mukherjee's The Song of The Cell is a beautifully crafted exposition of the author's own lifelong fascination with the subject

Wockhardt likely to sell India business to cut debt, focus on UK: Analysts

Company left with low-margin brands in India after selling profitable ones

Glenmark launches drug to treat patients with insulin-resistant diabetes

Glenmark Pharmaceuticals on Thursday said it has launched Thiazolidinedione Lobeglitazone in the country for the treatment of type 2 diabetes in adults. The Mumbai-based drug firm has launched the medication under the brand name LOBG and is priced at around Rs 10 per tablet. Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes among insulin-resistant diabetic patients, Glenmark Pharmaceuticals said in a statement. The company had received approval from the Indian drug regulator, Drug Controller General of India, for manufacturing and marketing Lobeglitazone, based on a randomised, double-blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older. "As per the International Diabetes Federation, diabetes affects 74 million adults in India, of which, around 40 per cent of them seem to be insulin-resistant... "We are proud to introduce LOBG; an innovative an

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

We're geared to launch a new molecule every 1-2 years: Biocon Biologics MD

In an interview, Arun Chandravarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda

Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

The geopolitical incidents of the recent past as well as the pandemic have not really helped cost pressure: Tambe

Eris sees a sweet spot as it forays into insulin market, eyes 10% share

Eris Lifesciences (Eris) is foraying into an oligopolistic insulin market with its own insulin brand this month

USFDA rejects Biocon, Viatris application for Insulin Aspart

The company will respond to the CRL to satisfy the FDA's requests